ZyVersa Therapeutics, Inc. (ZVSA) Financials

$0.61

south_east
-$0.01 (-1.68%)
Day's range
$0.55
Day's range
$0.61
$0$0-$2B-$2B-$4B-$4B-$6B-$6B-$8B-$8B-$10B-$10BEarning20202020202120212022202220232023202420245%5%4%4%3%3%2%2%1%1%0%0%Profit Margin
Profit Margin
Revenue
Earnings

ZVSA Income statement / Annual

Last year (2024), ZyVersa Therapeutics, Inc.'s total revenue was $0.00, and the percentage change from the previous year is not available. In 2024, ZyVersa Therapeutics, Inc.'s net income was -$9.41 B. See ZyVersa Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost of Revenue $0.00 $10,400.00 $10,400.00 $10,400.00 $10,400.00
Gross Profit $0.00 -$10,400.00 -$10,400.00 -$10,400.00 -$10,400.00
Gross Profit Ratio 0 0 0 0 0
Research and Development Expenses $1.78 B $3.21 M $5.41 M $2.12 M $6.47 M
General & Administrative Expenses $7.36 B $11.21 B $7.61 M $5.58 M $5.36 M
Selling & Marketing Expenses $0.00 -$11.20 B $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $7.36 B $11.20 M $7.61 M $5.58 M $5.36 M
Other Expenses $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expenses $9.14 B $14.41 M $13.01 M $7.70 M $11.83 M
Cost And Expenses $0.00 $14.42 M $13.01 M $7.70 M $11.83 M
Interest Income $0.00 $0.00 $427.54 $821.37 $516.45
Interest Expense $269.86 M -$457,000.00 $427,542.00 $821,366.00 $516,450.00
Depreciation & Amortization $13.49 M $10,400.00 $10,400.00 $10,400.00 $10,400.00
EBITDA -$9.14 B -$107.74 M -$11.67 M -$7.25 M -$12.16 M
EBITDA Ratio 0 0 0 0 0
Operating Income Ratio 0 0 0 0 0
Total Other Income/Expenses Net -$283.35 M -$93.33 M -$2.37 M -$379,785.00 -$850,108.00
Income Before Tax -$9.42 B -$107.75 M -$14.05 M -$8.08 M -$12.68 M
Income Before Tax Ratio 0 0 0 0 0
Income Tax Expense -$6.75 M -$9.46 M $745.05 M $821,366.00 $516,450.00
Net Income -$9.41 B -$98.30 M -$759.10 M -$8.91 M -$13.20 M
Net Income Ratio 0 0 0 0 0
EPS -848.03 -1089.67 -930.251 -173.656 -272.447
EPS Diluted -848.03 -1089.67 -930.251 -173.656 -272.447
Weighted Average Shares Out $11.10 M $97,503.00 $25,948.00 $46,552.00 $46,552.00
Weighted Average Shares Out Diluted $11.10 M $97,503.00 $25,948.00 $46,552.00 $46,552.00
Link